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SA-4-1BBL is a recombinant costimulatory molecule that is active in its soluble 
form and has pleiotropic effects on the functions of innate, adaptive, and regulatory 
immune cells. We have previously shown that SA-4-1BBL makes CD4
+ 
T conventional 






 T regulatory cells (Tregs). 
The mechanistic basis of this observation is the subject of this study. We demonstrate that 
Tconvs, but not Tregs, are the direct targets of SA-4-1BBL-mediated evasion of Treg 
suppression without contribution from antigen presenting cells (APCs). SA-4-1BBL 
engagement with its receptor, 4-1BB, on Tconvs resulted in the production of high levels 
of IL-2 cytokine that was necessary and sufficient in overcoming Treg suppression. 
Removal of IL-2 from culture supernatant restored Treg suppression and repletion of 
Tconv:Treg cocultures with exogenous recombinant IL-2 overcame suppression.  
In a series of studies our laboratory demonstrated the therapeutic efficacy of SA-
4-1BBL as an adjuvant component of subunit cancer vaccines in various preclinical 
rodent cancer models. Inasmuch as SA-4-1BBL contains streptavidin (SA) as a foreign 
bacterial protein, repeated vaccinations may generate anti-SA antibodies. Such antibodies 
may have positive or negative effect on the efficacy of the vaccines. Therefore, a series of 
vi 
 
studies were conducted to assess the potential impact of SA’s immunogenicity on the 
immuno-stimulatory function of SA-4-1BBL molecule. We demonstrated that repeated 
treatments with SA-4-1BBL generate both cellular and humoral immune responses 
against the SA portion of the molecule. Antibodies against SA neither blocked nor 
improved the costimulatory function of SA-4-1BBL on T cells. Importantly, pre-
immunization with SA-4-1BBL protein alone did not interfere with the therapeutic 
efficacy of a subunit vaccine consisting of the human papillomavirs (HPV) E7 tumor 
associated antigen (TAA) + SA-4-1BBL in the TC-1 cervical cancer tumor model. 
Surprisingly, pretreatment with SA-4-1BBL alone conferred protection regardless of the 
type of tumor tested.  
The robust anti-tumor function of SA-4-1BBL involved a communication bridge 
between CD4 and NK cells without significant contribution from CD8 cells or B cells. 
NK cells were found to be critical to the observed tumor suppression and required CD4
+
 
T cell help for protective efficacy at both priming and effector stages. Depletion of either 
NK or CD4 cells negated SA-4-1BBL’s anti-tumor protection. Moreover, the tumor 
suppressive effect of SA-4-1BBL was shown to be a bona fide property of this molecule, 
as immunizing mice with an agonistic antibody to 4-1BB receptor did not confer any 
protection against TC-1 tumors.   
The significance of understating the mechanisms underlying SA-4-1BBL’s mode 
of action provides new tools in the evolving field of cancer immunotherapy and 
prevention. The implications also extend to transplantation settings as well as infectious 
diseases where tipping the balance between Tregs and T effector cells (Teffs) plays a 
critical role in achieving desired outcomes. 
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CHAPTER 1: INTRODUCTION 
 
 
Costimulation as a critical signal for productive T cell responses 
 
T cells are the critical cell type in adaptive immunity. T cells require 3 standard 
signals for activation, proliferation, acquisition of effector function, and establishment of 
long-term memory. Signal 1 is usually provided through T cell receptor (TCR) 
interacting with Major Histocompatibility Complex (MHC) class I or II molecules on 
antigen presenting cells (APCs) loaded with processed antigens. Costimulation provides 
signal 2, while soluble factors and cytokines constitute signal 3. All signals together 
decide on the fate and differentiation of the T cell in concern (1). CD8
+ 
T cells for 
example interact with MHC-I during viral infections or in the presence of intracellular 
pathogens and acquire effector functions capable of clearing the infection of concern. 
CD4
+ 
T cells on the other hand interact with MHC-II molecules and convert from their T 






 T regulatory cells 
(Tregs) , based on the antigen and type of costimulation engaged (Illustration 1). More 
importantly, the lack of costimulation leads to T cell anergy and unresponsiveness 




Illustration 1. Guarner et al. Nature Clinical Practice Gastroenterology & 
Hepatology (2006) 3, 275-284.   
 
Costimulatory molecules in general are categorized into two wider families: 
CD28 and tumor necrosis factor receptor (TNFR) superfamily. CD28 for example is 
constitutively expressed on T cells and interacts with B7 molecules on APCs to drive 
activation of T cells. CD28 action is usually maintained under control by its competitor 
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), also expressed on T cells and 
delivers inhibitory signals when interacting with B7 at higher affinity (2). TNFR family 
members on the other hand, such as 4-1BB, OX40, and CD27 (Illustration 2), are 




), Tregs, NK cells, mast cells, 
and neutrophils (3). The inducible expression on antigen-experienced T cells is 
advantageous for the expansion of antigen-specific immune responses in therapeutic 




Illustration 2. Michael Croft, Nature Reviews Immunology (2003) 3. 609-620. 
 
 
TNFR family members in costimulation 
 
There are 27 TNF-ligands identified so far with biological functions. Ligand/receptor 
pairs with costimulatory signaling capacity include CD40L (CD154)/CD40, CD70/CD27, 
4-1BBL/4-1BB (CD137), OX40L/OX40 (CD 134), GITRL/ GITR (CD 357), and 
HVEMLs/ HVEM (CD 270), that have showed promise as therapeutic modulators of T 
cell immunity (4). 
CD40L/CD40: CD40L expression has been identified on activated B cells, epithelial 
cells, endothelial cells, platelets, smooth muscle cells, and DCs. Expression of its 
receptor CD40 is found on B-cells, monocytes, macrophages, platelets, DCs, eosinophils, 
and activated CD8
+





“license” DCs to prime effective cytotoxic CD8+ T-cell responses. In its absence 
“unlicensed” DCs induce T-cell anergy or T-cell deletion and generate regulatory T cells 
(5, 6). 
CD70/CD27: The expression of CD70 is restricted to activated T and B lymphocytes and 
mature DCs. CD27 is a type I transmembrane receptor expressed on naive T cells, mature 





 T cell responses and enhance T-cell survival and effector 
functions. CD70/CD27 signaling promotes the development of CD4
+
 T cells that are able 
to produce Th1 and Th2 cytokines (7). 




 T cells, NK 
cells, NKT cells, and neutrophils. OX40L is primarily expressed by APCs such as DCs, 
B-cells, and macrophages. OX40 provides a co-stimulatory signal to TCR-stimulated T 
cells and enhances clonal expansion, proinflammatory cytokine production, and 
generation of memory CD4 T cells. Furthermore, OX40 promotes CD8 T cells survival 
and expansion directly or indirectly via the induction of CD4 T-helper responses (8). 




 T cells, DCs, 
monocytes, and NK cells. GITR ligand (GITRL) is highly expressed on activated APCs 
and endothelial cells (ECs), and it promotes leukocyte adhesion and transmigration (9). 
Moreover, GITR ligation has been shown to break self-tolerance and abrogate T-cell 
suppression by Tregs, which could be utilized as a target for cancer immunotherapy (10). 
HVEMLs/HVEM: The Herpesvirus entry mediator (HVEM) expression is in fact 
opposite to 4-1BB, OX40, and GITR expression patterns. HVEM is highly expressed on 
naive and memory B cells as well as resting T cells, but down regulates upon B and T 
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cell activation. There are four ligands for HVEM: CD160 (a member of the Ig 
superfamily); B- and T-lymphocyte attenuator (BTLA); LIGHT; and lymphotoxin-alpha. 
Interaction of CD160 and BTLA with HVEM inhibits B and T cell activation, while 
interaction of LIGHT or lymphotoxin-alpha with HVEM triggers T and B cell activation 
and APC maturation and differentiation (11). 
 
4-1BB costimulation and signaling background 
 
4-1BB, also known as CD137/TNFSF9, is a member of TNFR superfamily (12). 
It is a costimulatory molecule that is upregulated on the surface of lymphoid cells such as 
T cells, B cells, and NK cells when activated and non-lymphoid cells such as dendritic 
cells (DCs), macrophages, neutrophils, and malignant tumor endothelial cells (13). Upon 
4-1BB receptor clustering, a heterotrimer is formed consisting of TNF-receptor 
associated factors (TRAFs) where two molecules of TRAF2 combine with one molecule 
of TRAF1. TRAF2 initiates a signaling cascade of mitogen-activated protein (MAP) 
kinases and NF-κB activation, which in turn leads to the production of more TRAF1 that 
sustains the effect of 4-1BB costimulation. TRAF1 favors extracellular signal-regulated 
kinase (ERK) pathways (Illustration 3). The end result is the expansion and survival of T 
cells, acquisition of effector functions, and establishment of long-term memory (14, 15). 




Illustration 3. Chao Wang, Tania H. Watts. Cytokine & Growth Factor Reviews (2012) 
23, 245–254. 
 
More recently 4-1BB costimulation has been shown to reduce T cell exhaustion in 
ex vivo settings where there is persistent antigen exposure. The authors in the study used 
genetically engineered T cells that express chimeric antigen receptors (CARs) capable of 
recognizing specific antigens and activating T cells independent of MHCs. Contrary to 4-
1BB, CD28 costimulation in the CAR model has been shown to enhance exhaustion (16). 
In a transplanted melanoma model, Curran et al. have shown that mice treated with anti-
4-1BB antibodies generate novel forms of CD4
+
 killer and CD8
+
 killer tumor infiltrating 
T cells characterized by the expression of  killer-cell lectin like receptor G1 (KLRG1)  
and the transcription factor Eomesodermin (Eomes) independent of  the T-box 
transcription factor (T-bet) expression. These cells were shown to produce granzymes 
capable of killing melanoma cells. In addition to that, amongst the members of TNFR 





phenotype, while anti-OX40, anti-GITR, and anti-CD27 could not (17).       
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It is important here to also shed light on the regulatory aspects of 4-1BB signaling 
as it plays a double edged sword by generating and expanding effector immunity as well 
as expanding and promoting Treg functions and redirecting T cell polarization. In mice 
for example, 4-1BB is constitutively expressed on Tregs and can respond to 4-1BBL + 
IL-2 + TGF-β stimuli to induce their proliferation. The duality of 4-1BB function seems 
to be at least partially controlled by Galectin-9, a member of the β-galactoside–binding 
family of lectins (18). Upon addition of anti-4-1BB antibody (clone 3H3), Gal-9 binds to 
4-1BB on the cell surface without competing with the binding sites of the ligand nor 3H3. 
Gal-9 binding is demonstrated to be required for the ability of 4-1BB signaling to  
suppress experimental autoimmune encephalomyelitis (EAE) and allergic asthma in vivo 
(18). In another study, 4-1BB ligand was shown to play a regulatory role in T cells that 
are weakly activated under suboptimal conditions below the threshold of 4-1BB 
expression and activation. Once the activation threshold was met, cell intrinsic 4-1BB 
was shown to downregulate the expression of 4-1BBL by endocytosis and internalization 
(19). This balance between the ligand and the receptor is necessary for maintaining 
immune system homeostasis.         
 
4-1BB in Cancer Vaccines 
  
Cancer vaccines usually consist of two major categories: 
Prophylactic/preventative such as Gardasil® and Cervarix® against Human 
Papillomavirus (HPV) 16 and 18, or therapeutic such as the dendritic cell based vaccine 
(Sipuleucel-T) approved by the FDA in the USA on 2010. The down side of DC vaccines 
is that they are relatively expensive, need to be subject customized, and are technically 
challenging to produce. Subunit vaccines consisting of tumor associated or specific 
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antigens and immune-adjuvants, are more economically feasible and present as effective 
alternatives to cell-based vaccines with ease of production and marketing. The culprit in 
the subunit vaccines is that the immunogenicity of most antigens is low, most of them 
being self antigens, as well as the lack of potent and safe vaccine adjuvants capable of 
overcoming tumor immune evasion mechanisms. As such, in the absence of predefined 
tumor specific antigens and alongside conventional chemotherapy, scientists have started 
incorporating alternative immune modulators in clinical cancer therapies, such as the use 
of monoclonal antibodies targeted towards tumors and/or cells of the immune system. 
Some of the clinically approved candidates include i) the monoclonal antibody Herceptin 
(Trastuzumab) directed towards breast cancer cells expressing the human epidermal 
growth factor receptor 2 (Her2) protein (20). ii) Ipilimumab, an anti-CTLA antibody, 
which blocks the action of Tregs giving more room for Teffs and NK cells to carry out 
their killer functions (21). iii) Antibodies blocking the programmed death receptor-1 (PD-
1) that is usually expressed by activated lymphocytes and delivers an inhibitory signal 
when associated with its ligand expressed by APCs as well as tumors (22). iv) Agonistic 
antibodies to 4-1BB costimulatory receptor, especially picked from the tumor necrosis 
factor superfamily due to its promising pre-clinical and clinical outcomes in fighting 
tumors and activating a wide array of effector immune cells.  
The major drawback of anti-4-1BB antibodies is the high level of associated 
toxicity as reported by several studies in rodents and humans (15). Toxicity profiles are 
usually characterized by non-specific activation of immunity resulting in systemic 
inflammation, splenomegaly, lymphadenopathy, increased liver enzymes AST/ALT, as 
well as hepatitis. The observed toxicity is shown to be independent of FcγR or 
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 T cells was noted upon immunizing naïve C57BL/6 mice with anti-4-1BB antibody 
clone 3H3 accompanied with high levels of IFN-γ and TNF-α production. Higher doses 
of 3H3 also abrogated T helper cell dependent humoral immunity, caused more 
hepatomegaly, as well as anemia and disturbance in bone marrow’s cellular compartment 
(24). 
 
SA-4-1BBL as a potent adjuvant 
 
Taking into account the various toxic facets of agonistic 4-1BB antibody 
treatments and the fact that naturally occurring 4-1BBL is inactive in its soluble form 
unless bound to a cell surface membrane, our lab has generated and produced a novel 
soluble form of 4-1BBL adjuvant by fusing the extracellular domain of murine 4-1BBL 
to the C-terminus of a modified core streptavidin (SA). SA forms stable tetramers and 
oligomers which is important to cluster the 4-1BB receptors on corresponding cells and 
enhance signal transduction (Illustration 4). Side by side comparison studies between 
soluble SA-4-1BBL and 3H3 have shown SA-4-1BBL to be more potent activator than 
3H3 while lacking the antibody associated toxicity (23). Our lab has conducted a series of 
extensive studies demonstrating the in vitro and in vivo pleiotropic functions of SA-4-




Illustration 4. SA-4-1BBL structural representation. Shirwan’s Lab, 2016. 
SA-4-1BBL adjuvant effect on adaptive immunity 
 
In our attempt to develop subunit based therapeutic cancer vaccines using defined 
TAAs, SA-4-1BBL was shown to act on CD4
+
 as well as CD8
+
 T cells to fulfill its potent 
adjuvant role in the designed vaccine formulations. Depletion of CD4
+
 T cells 1 day prior 
tumor inoculation in two transplantable models (TC-1 cervical cancer expressing Human 
Papillomavirus antigen E7; and 3LL lung carcinoma overexpressing the self antigen 
survivin) was shown to significantly reduce the therapeutic vaccine efficacy administered 
6 days later from tumor challenge (25). Upon rechallenge of tumor free mice, long term 
immunological memory was also lost in the absence SA-4-1BBL effect on CD4
+
 T cells. 
In another study using survivin + SA-4-1BBL vaccine in 3LL model, 100% of tumor 
eradication was achieved in a prime-boost vaccination strategy. Depletion of CD8
+
 T 
cells producing IFN-γ 1 day prior vaccinations completely compromised therapeutic 
efficacy while depletion of NK cells had moderate yet noticeable effect on tumor growth. 
NK cells isolated from immunized mice showed improved killing against YAC-1 target 
cells in vitro (26).              
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SA-4-1BBL adjuvant effect on innate immunity 
 
Switching gears towards innate immunity, SA-4-1BBL’s direct or indirect effect 
on NK cells has been shown to be indispensable for HPV-16 E7 recombinant protein- 
based therapeutic vaccine in the TC-1 murine tumor model. Eradication of established 
tumors was mainly dependent on 4-1BB signaling as C57BL/6.4-1BB knockout 
(C57BL/6.4-1BB
−/−
) mice failed to clear the tumors and expired accordingly (27). 
Activated NK cells have been shown in the literature to express 4-1BB receptor 
themselves and are involved in the eradication of P815 mastocytoma in vivo although 
they lack the in vitro lysis function upon stimulation with anti-4-1BB monoclonal 
antibody, suggesting an immuno-regulatory role of NK cells in this case as compared to 
direct killing and effector functions (28). NK cells isolated from human peripheral blood, 
activated with IL-2/IL-15 cytokines for 48 hours to upregulate 4-1BB, and incubated with 
the MCF-7 human breast cancer cell line overexpressing 4-1BBL for additional 12 hours, 
have been shown to upregulate perforin, granzyme B, and FasL genes without enhancing 
cellular degranulation nor IFN-γ production upon engagement of 4-1BB with 4-1BBL on 
MCF-7 cells (29).  
Dendritic cells (DCs) of the innate immune system on the other hand, produce a 
variety of cytokines such as TNF-α, IL-6, and IL-12 upon 4-1BB stimulation (30, 31). 
SA-4-1BBL not only provides robust immune costimulatory activity in DCs in 
therapeutic cancer vaccines but also contributes to the delivery of TAAs conjugated 
through biotin to the streptavidin portion of the molecule (32). DCs in turn engulf the SA-
4-1BBL-TAA conjugate and enhance antigen presentation to T cells. TC-1 or 3LL tumor 
bearing mice showed significant improvement in survival upon administering SA-4-
12 
 
1BBL-TAA conjugate vaccine on day 6 post-tumor challenge versus administering SA-4-
1BBL + TAA without conjugation. The therapeutic efficacy of the vaccine was 
associated with higher tumor infiltrating CD8
+
 T cells to Tregs ratio (32).  
Another study conducted in our lab has recently aimed at simultaneous 
stimulation of innate and adaptive immunity in fighting tumors using a combination of 
the Toll-like receptor 4 (TLR4) agonist called monophosphoryl lipid A (MPL) plus SA-4-
1BBL. One vaccination with the combination of both adjuvants and HPV E7 protein as 
TAA resulted in 100% survival in murine TC-1 model. Vaccine formulation containing 
SA-4-1BBL had better efficacy (~80%) than formulation with MPL alone (~50%) (33). 
 
SA-4-1BBL’s role in regulatory immunity 
 
 SA-4-1BBL has a major impact on regulatory immunity. SA-4-1BBL drives the 
proliferation of activated Tregs when combined with the cytokine IL-2 while maintaining 
Tregs’ suppressive function (34). Tregs constitutively express the IL-2 and 4-1BB 
receptors and SA-4-1BBL costimulation further upregulates the expression of both 
receptors. This regulatory aspect of SA-4-1BBL was shown to overcome autoimmune 
diseases and prevent graft rejection (34). On the other hand, we showed that SA-4-1BBL 
without exogenous IL-2 blocks the conversion of conventional CD4
+
 T cells into induced 
Tregs through the production of IFN-γ (35). One of the important mechanisms by which 
tumors evade suppression is the induction of iTregs in the tumor microenvironment and 
SA-4-1BBL has the ability to block the accumulation of iTregs even in the presence of 
tumor antigens and TGF-β pressure. In the process of exploring the effects of SA-4-
1BBL on Tregs, we have observed that Teffs themselves become resistant and refractory 
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to suppression by Tregs (34, 36), the mechanism of which is yet unknown and will be 
elucidated in the subsequent chapter of this dissertation. 
In summary, 4-1BB signaling has pleiotropic effects in modulating the immune 
system by acting on all 3 branches: innate, adaptive, and regulatory immunity. These 
effects are content- and model- dependent and need to be carefully considered when 




CHAPTER 2: SA-4-1BBL LIBERATES CONVENTIONAL T CELLS FROM 










 Tregs comprise a distinct and important cell type that confers 
peripheral tolerance. Deficiencies in Tregs or their regulatory function are associated with 
severe autoimmunity in rodents and humans. Their presence or absence has high impact 
in transplantation as well as tumor settings. They can mediate graft survival, but can also 
abrogate effector T cells from carrying their killing function in tumor microenvironments 











 but convert into 
Foxp3
+ 
upon induction in the periphery. Other subtypes include Tr1 and Th3 iTregs that 
are Foxp3
- 
but are specialized in IL-10 and TGF-β production (38). Although 4-1BB 
receptor is constitutively expressed on Tregs in mice, our lab has previously shown that 
in Teff:Treg co-culture experiments, SA-4-1BBL drives the proliferation of Teffs without 
altering the suppressive functions of Tregs. Tregs pre-incubated with SA-4-1BBL prior 
addition to suppression assays did not cease their suppressive function (34). Moreover, 
cultures with Tregs sorted from C57BL/6. 4-1BB
-/-  
mice and incubated with sorted Teffs 
from wild type C57BL/6 mice in the presence of SA-4-1BBL showed high proliferation 
of Teffs proving that evasion of suppression is not due to direct engagement of SA-4-
1BBL with its receptor on Tregs (36). Combining our
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observations together, we hereby shifted our focus to study the direct mode of action of 
SA-4-1BBL on conventional T cells (Tconvs) and the mechanism(s) underlying the 
escape from suppression.  
 
Materials and Methods  
 




 and wild type C57BL/6 mice were purchased from The 
Jackson Laboratory. C57BL/6.Foxp3
hCD2
 mice (39) and 4-1BB knockout mice (40) were 
bred and cared for in University of Louisville’s SPF-free vivarium in accordance with 
NIH guidelines. All animal procedures were approved by the University of Louisville’s 
Institutional Animal Care and Use Committee. Antibodies used include anti-CD3 
agonistic Ab (clone 145-2C11, BD Pharmingen, Cat# 553058), anti-TGF-β (1,2,3) 
neutralizing Ab (clone 1D11, homemade), anti-IFN-γ blocking Ab (clone XMG 1.2, 
homemade), and anti-IL-2 neutralizing Ab (clone S4B6, BD Pharmingen, Cat# 554375). 
Fluorescein-conjugated Abs to various cell surface markers were obtained commercially: 
anti-CD4-APC (BD Pharmingen, 553051); anti-CD25-PE (BD Pharmingen, 553866); 
anti-CD25-PE-Cy7 (eBioscience, 25-0251-82); anti-hCD2-PE (BioLegend, 300208). 
Where indicated Tconvs or Tregs were stained with 2.5µM CFSE (Invitrogen, C1157). 
CTLL-2 cell line was obtained from ATCC (TIB-214). Human IL-2, SA-4-1BBL, and 
SA proteins were produced in our lab according to standard protocols as previously 










Both Tconvs and Tregs were sorted from splenocytes of naive C57BL/6.Foxp3
GFP
 mice 












population to collect Tregs. Tconvs from WT C57BL/6 or Tregs from 
C57BL/6.Foxp3
hCD2 








+ to collect Tregs. Sorted populations purity was ≥ 99%. 
 
Ex-vivo expansion of Tregs 
 
In select experiments, Tregs were expanded using our previously described protocol (34). 
Briefly, 1 x 10
5 
to 5 x 10
5 
sorted Tregs were cultured in a 6 well plate in addition to 1 x 
10
6 
irradiated C57BL/6 splenocytes (2000 cGy); anti-CD3 antibody (0.5 µg/ml); SA-4-
1BBL (1 µg/ml); IL-2 cytokine (25 IU/ml). Cells were cultured for 4 days at 37
o
C, 5% 
CO2 after which 1 ml of culture media was displaced with 1 ml fresh MLR media and 
supplemented with IL-2 (25 IU/ml). On day 7, cells were collected, centrifuged, washed 
and resuspended in fresh MLR media for additional 3 days with IL-2 only (25 IU/ml).  
On day 10, cells were washed and rested without IL-2 for two to three days (while 
checking viability) prior addition to suppression assays. Expanded Tregs maintain their 
Foxp3 expression as tested by flow cytometry (data not shown) and retain their 
suppressive functionality.  
 
Suppression assays with and without APCs 
 
Freshly sorted Tconvs (2.5 x 10
4
) were cocultured in 96-well U-bottom plates with 
freshly sorted or expanded Tregs (2.5 x 10
4
) plus irradiated naive C57BL/6 splenocytes 
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as source of APCs (1 x 10
5 
, 2000 cGy). Cultures were supplemented with anti-CD3 Ab 
(0.5 µg/ml), SA-4-1BBL (1 µg/ml), and IL-2 (3 IU/ml) where indicated. In absence of 
APCs, Tconvs and Tregs were cultured with plate bound anti-CD3 (5 µg/ml), while 
maintaining the rest of the conditions constant. Coculture plates were incubated for 48 h 
(37
o 
C, 5% CO2) and pulsed with 1 μCi/well of [
3
H]-thymidine (PerkinElmer, Cat# 
NET027X001MC) for an additional 16 h. Plates were harvested using Tomtec cell 
harvester and counts per minute (CPMs) were recorded using Wallac Betaplate liquid 
scintillation counter as a measure of cell proliferation. 
Cytometric bead array 
 
Th1/Th2/Th17 panel of cytokine beads (BD Biosciences, Cat# 560485) were used to 
measure IL-2, IL-4, IL-6, IFN-γ, TNF-α, and IL-17a levels in cell culture supernatants 
following manufacturer's instructions. Concentrations of the various cytokines were 
calculated against a standard that runs from 0-5000 pg/ml.  
 
RT-PCR for IL-2 expression 
 
Tconvs and Tregs were sorted from splenocytes of naive C57BL/6.Foxp3
GFP
 mice using 












population to collect Tregs.  Cocultures were stimulated with SA-4-1BBL (1 
µg/ml) and plate-bound anti-CD3 Ab (5 µg/ml).  Cultures were harvested for total RNA 
isolation 24 and 48 hours post-stimulation.  RNA was converted into cDNA and used for 
real-time PCR amplification using primers for housekeeping gene glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) and IL-2.  Primer sequences (GenScript) were as 
follows: IL-2 forward 5’-TGA GCA GGA TGG AGA ATT ACA GG-3’, reverse 5’-GTC 
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CAA GTT CAT CTT CTA GGC AC-3’; GAPDH forward 5’-CCA TCA CCA TCT TCC 
AGG AGC GAG-3’, reverse 5’-CAC AGT CTT CTG GGT GGC AGT GAT-3’. Delta-
Delta CT values were calculated and normalized to GAPDH. 
 
Removal of SA-4-1BBL and IL-2 from Tconv culture supernatant  
 
Supernatants were generated from 96 well cultures of (Tconvs + 5 µg/ml plate 
bound anti-CD3 + 1 µg/ml SA-4-1BBL) incubated for 48 hours at 37
o 
C, 5% CO2. Taking 
advantage of the 6xHis tag engineered into the SA-4-1BBL molecule, culture 
supernatants were incubated with CuSO4-charged sepharose beads for 15 minutes at 
room temperature followed by centrifugation and aspiration of the SA-4-1BBL-cleaned 
supernatant. 
IL-2 was removed by incubating supernatants with anti-IL-2 neutralizing antibody 
(20µg/ml, clone S4B6) to form complexes at 37
o 
C for 15-30 minutes. Ab/IL-2 
complexes were then removed by incubating with Immobilized Protein G high affinity 
beads (Thermo Scientific, Cat# 20398). IL-2-cleaned supernatant was tested on CTLL-2 
cells that require IL-2 cytokine as a limiting factor for their growth. CTLL-2 cells were 
plated in U-bottom 96 well plates (5000 cells/50µl + 50µl supernatant cleaned from SA-
4-1BBL only as positive control, or cleaned from SA-4-1BBL and IL-2). Cultures were 
incubated for 28 hours total at 37
o 
C, 5% CO2 with addition of [
3
H]-thymidine for the last 
8 hours. Cells were harvested using Tomtec cell harvester and proliferation of CTLL-2 










Each data point represents the mean ± SEM of triplicate wells unless otherwise stated. 
The statistical significance between data points was estimated with two-tailed Student’s t 





APCs do not contribute to SA-4-1BBL-mediated evasion of Treg suppression 
 
In previously published studies, we have demonstrated that SA-4-1BBL 
costimulation allows Tconvs to overcome Treg suppression (36). These studies were 
conducted using Tregs and Tconvs cocultured with APCs from C57BL/6 wild type mice. 
The 4-1BB receptor is expressed on a subpopulation of DCs and stimulation via this 
receptor results in the secretion of various cytokines, such as IL-6, IL-12, and TNF-α (30, 
31). To assess the potential contribution of signaling in APCs to the observed Tconv 
evasion of Treg suppression, suppression assays were performed with irradiated 
splenocytes from wild type as well as 4-1BB KO mice. SA-4-1BBL overcame the 
suppression of sorted Tconvs cultured by Tregs. More importantly, Tconvs cocultured 
with 41BB
-/-
 APCs showed robust proliferation responses when costimulated with SA-4-
1BBL in the absence or presence of Tregs (Fig. 1). These responses were comparable to 
those generated with wild type APCs.   
To further confirm that APCs do not play a role in the Tconv evasion of Treg 
suppression, the coculture studies were performed in the absence of APCs.  Stimulation 
of Tconvs with plate bound anti-CD3 Ab alone under these culture conditions did not 
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generate a significant proliferative response (Fig. 2).  However, costimulation with SA-4-
1BBL resulted in robust Tconv proliferation that was refractory to suppression by Tregs. 
Taken together these data demonstrate that costimulation via 4-1BB receptor expressed 
on APCs is not involved in SA-4-1BBL-mediated Tconv resistance to suppression by 
Treg cells. 
 
TGF- and IFN do not contribute to SA-4-1BBL-mediated evasion from Treg 
suppression 
 
TGF-β has been shown to play an important role in the generation of Tregs and 
their suppressor function (43-45). We therefore envisioned that SA-4-1BBL stimulation 
may overcome the Treg mediated suppression by modulating the function of TGF-β. A 
neutralizing Ab against TGF-β at two different doses (8 and 50 µg/ml) did not neutralize 
Treg suppression nor did it further improve the observed SA-4-1BBL-mediated evasion 
of Treg suppression (Fig. 3).  
It has been demonstrated that T cells in response to T-cell receptor signaling 
produce an active form of TGF-β, which is adsorbed to the cell surface immediate post-
secretion (46). Membrane-bound TGF-β could act as a mediator for Treg suppression 
(47). Therefore, to eliminate the possibility that SA-4-1BBL may overcome Treg 
suppression by modulating the function of membrane-bound TGF-β, we sorted Tregs and 
pre-incubated them with high dose anti-TGF-β Ab (50 µg/ml) for 1 hour prior addition to 
coculture suppression assays. These cells were able to suppress Tconvs and costimulation 
with SA-4-1BBL was still able to overcome suppression (Fig. 4). 
SA-4-1BBL costimulation of Teffs results in their secretion of IFN-γ, which 
blocks TGF-β and tumor-mediated conversion of these cells into induced Tregs (35).  
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However, opposite findings show that IFN-γ may also contribute to the conversion of 
Tconvs into peripheral Tregs and improve their suppressive function by upregulating 
Foxp3 gene expression (48). To study the potential role of this cytokine in the observed 
SA-4-1BBL-mediated evasion of Treg suppression, we performed suppression assays 
with a blocking Ab against IFN-γ (25 µg/ml). The antibody added to the cocultures did 
not block the suppression of Tconvs by Tregs, also it provided evidence that IFN-γ is not 
responsible for the evasion of suppression in the presence of SA-4-1BBL (Fig. 5). These 
observations are consistent with previous findings that IFN-γ has no direct effect on 
natural thymic Treg development and function (49). 
 
IL-2 is the major cytokine produced in the supernatant of Tconv:Treg cocultures 
costimulated with SA-4-1BBL 
 
In an attempt to identify potential soluble factors that contribute to the Tconv 
evasion of Treg suppression, we assessed cytokines generated in coculture supernatants 
in response to SA-4-1BBL costimulation using cytokine bead array analysis. As shown in 
(Fig. 6), costimulation of Tconvs with SA-4-1BBL resulted in upregulated secretion of all 
cytokines tested except IL-17. IL-2 and TNF- production levels were particularly 
increased in the 48 hour culture supernatants of Tconvs + SA-4-1BBL.  However, the 
levels of these two cytokines were similar in supernatants harvested from Tconv:Treg 
cocultures with or without SA-4-1BBL costimulation. This cytokine pattern was not time 
dependent as 24 hour culture supernatants showed a similar pattern (data not shown).   
 The presence of APCs and particularly their irradiation may impact overall 
cytokine production and secretion into the coculture supernatants. Therefore, these 
studies were performed with sorted Tconvs and Tregs in the absence of APCs. IL-2 stood 
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out as the highlight cytokine with significant and robust production in supernatants 
harvested from Tconvs, as well as Tconv:Treg cocultures costimulated with SA-4-1BBL, 
but not in culture supernatants without SA-4-1BBL costimulation (Fig. 7). The lack of 
high levels of IL-2 in cultures with irradiated APCs may be due to its non-specific 
binding or consumption by such cells, or other unknown mechanisms.  
 We also noticed a significant drop in the levels of IL-2 in Tconv:Treg cocultures 
stimulated with SA-4-1BBL (Fig. 6 and 7) versus Tconvs + SA-4-1BBL cultures. To test 
if this is due to IL-2 produced by Tconvs being consumed by Tregs that do not produce 
significant levels of this cytokine, we performed quantitative RT-PCR to assess the level 
of IL-2 mRNA under various culture conditions. As shown in Figures 8A and 8B, IL-2 
transcript levels were comparable between Tconv and Tonv:Treg cocultures stimulated 
with SA-41BBL examined at 24 and 48 h time points. Taken together, these data suggest 
that the reduced levels of IL-2 protein observed in supernatant of Tconv:Treg coculture 
stimulated with SA-4-1BBL is not due to the diminished IL-2 transcript levels, but 
possibly because of the consumption of this cytokine by Tregs.        
 
IL-2 is necessary and sufficient for Tconvs to overcome Treg suppression  
 
 The high levels of IL-2 production in Tconv:Treg cocultures costimulated with 
SA-4-1BBL has captured our interest to test the role of this cytokine in the evasion of 
Treg suppression. Culture supernatants from Tconvs + plate-bound anti-CD3 + SA-4-
1BBL for 48 h were harvested and depleted for SA-4-1BBL protein using CuSO4 charged 
sepharose beads, taking advantage of the 6xHis Tag engineered into the protein for 
purification purposes. The complete removal of SA-4-1BBL was confirmed by Western 
blots (Fig. 9). We next subjected this supernatant for removal of IL-2 by first incubating 
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with an excessive amount of an anti-IL-2 Ab followed by incubation and removal using 
protein G beads. The lack of IL-2 in culture supernatant was confirmed in a CTLL-2 
proliferation assay (Fig. 10). Tconv culture supernatants lacking SA-4-1BBL or both SA-
4-1BBL and IL-2 were tested for their ability to overcome Treg suppression. Addition of 
SA-4-1BBL-free culture supernatant resulted in effective evasion of suppression in 
Tconv:Treg coculture experiments with (Fig. 11A) or without APCs (Fig. 11B). On the 
other hand, culture supernatant lacking both SA-4-1BBL and IL-2 was ineffective in 
overcoming Treg suppression. To further confirm that IL-2 is required for overcoming 
Treg suppression, Tconv:Treg cocultures were supplemented with recombinant IL-2.  
Exogenous IL-2 resulted in robust proliferative responses in both Tconv and Tconv:Treg 
cocultures (Fig. 11A, 11B).  
 
IL-2-mediated Tconvs evasion of Tregs suppression is independent of Tregs 
proliferative state 
 
In environments where IL-2 is not a limiting factor, both Teffs and Tregs are 
known to proliferate upon primary stimulation such as during inflammatory insults (50). 
A previous publication by our group also indicates that SA-4-1BBL causes the 
proliferation of both Teffs and to a lower extent Tregs (34). Putting one and two together 
we have stained either Tconvs sorted from C57BL/6 or Tregs sorted from 
C57BL/6.Foxp3
hCD2
 splenocytes with CFSE prior addition to suppression assays. The 
CFSE labeled Tconvs proliferated by 67.5% with SA-4-1BBL and by 64.1% in the 
presence of Tregs and SA-4-1BBL. The CFSE labeled Tregs on the other hand 
proliferated by 11.1% with SA-4-1BBL and by 27.3% in the presence of Teffs and SA-4-
1BBL (Fig. 12). One might claim here that when Tregs are in an active proliferative state 
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they might lose their suppressive capacity and the Tconvs can evade and over-proliferate. 
In fact, Tregs at their anergic non-proliferative state are shown to be better suppressors 
(51). 
To eliminate the contribution of Treg proliferation to the observed evasion of 
suppression achieved by SA-4-1BBL, we irradiated sorted-expanded Tregs with 2000 
cGy before utilizing them in suppression assays. The irradiated Tregs did not proliferate 
upon addition of exogenous IL-2 or SA-4-1BBL and they still maintained their 
suppressive function (Fig. 13). More interestingly, when we added SA-4-1BBL to the 
cocultures in the presence of irradiated Tregs, Tconvs were still able to proliferate 
significantly and escape the suppressive non-proliferative Tregs, which gives us further 
confirmation that the mechanism is through IL-2 acting directly on Tconvs in an 
autocrine fashion.  
 
Discussion  
    
Our first experiment aimed at reproducing the evasion of suppression data from 
previous studies in the lab in the presence and absence of SA-4-1BBL in coculture 
suppression assays (36), only this time we have used splenocytes from 41BB
-/- 
mice as 
source of irradiated APCs along with soluble anti-CD3. The reason was to eliminate any 
interference of 4-1BB receptor on the surface of APCs binding with SA-4-1BBL and 
causing the leakage of cytokines such as IL-6, TNF-α, and IL-15, despite irradiation. 
Sorted Tconvs cultured with 41BB
-/-
 APCs proliferated successfully in the presence of 
SA-4-1BBL and were able to escape suppression when co-cultured with Tregs. The 
finding further emphasizes the direct effect of SA-4-1BBL on Tconvs. More Importantly, 
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SA-4-1BBL conferred Tconv resistant to Treg suppression in the complete absence of 
APCs.  
In an attempt to understand the mechanism of evasion, we initially hypothesized 
that if Tregs suppress primarily through TGF-β, SA-4-1BBL might be downregulating 
TGF-β receptor II on Tconvs, hence desensitizing them to suppression (52). Adding anti-
TGF-β neutralizing antibody to the specified cultures (8 µg/ml and 50 µg/ml) did not 
block the suppression of Tregs and did not improve the evasion levels noticeably. These 
findings are in accordance with published studies demonstrating that thymically derived 
(t)Tregs suppress through cell-to-cell contact without a significant contribution by TGF-β 
(51, 53). Signaling via 4-1BB receptor on T cells results in IFN-γ production that has the 
ability to block TGF-β and tumor-mediated conversion of Tconvs into iTregs (35). On 
the other hand, IFN-γ contributes to the conversion of Tconvs into iTregs and enhances 
their suppressive function through upregulation of the forkhead box P3 (48). However, 
these divergent observations are conducted under different experimental setups as the 
first study has used TGF-β and antigen stimulation-dependent conversion, while the 
second study has utilized antigen- and a TGF-β-independent conversion setting. In the 
present study, a blocking Ab to IFN-γ (25 µg/ml) neither prevented Treg suppression in 
the absence of SA-4-1BBL, nor altered SA-4-1BBL-mediated evasion of suppression. 
Our data supports previous findings stating that IFN-γ has no direct effect on (t)Tregs 
development and function (49). 
IL-4 may be another cytokine yet that regulates the balance between Teffs and 
Tregs in a twofold fashion: acting on Teffs and activating STAT 6 pathway on one hand 
making Teffs resistant to suppression (54, 55), or on the other hand IL-4 may act on 
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Tregs and activate GATA 3 that binds in turn to Foxp3 and blocks it (56, 57). The same 
studies have reported that the effect of IL-4 is pronounced in iTregs and not nTregs in 
general, which dramatically drops the odds of IL-4 involvement in our study since we 
have sorted nTregs from naïve mice that are Foxp3
+
.  
IL-2 expressed by Tconvs is required and sufficient for the ability of these cells to 
evade Treg suppression under the tested coculture conditions. First, IL-2 was the major 
cytokine upregulated in cocultures stimulated with SA-4-BBL in the absence of APCs.  
Second, supernatant from SA-4-1BBL-stimulated cultures was effective in overcoming 
Treg suppression, and removal of IL-2 nullified this effect. Third, exogenous 
recombinant IL-2 alone was effective in overcoming Treg suppression. Competition for 
IL-2 has been shown to be an important mechanism that dictates the functional balance 
between Tconvs and Tregs. The receptor for IL-2 is a trimeric complex consisting of IL-
2Rα (CD25), IL-2Rβ (CD122), and IL-2Rγ (CD132). The high affinity receptor CD25 is 
constitutively expressed on nTregs while it is upregulated upon induction on Teffs. IL-2 
is also known to be a growth factor for Tregs (58), more specifically IL-2 stabilizes the 
expression of Foxp3 in iTregs in the presence of TGF-β (59). Our observation is 
explained by the fact that in the presence of weak signals such as anti-CD3 and low levels 
of IL-2, Tregs that constitutively express CD25 drain all the IL-2 and deprive the Tconvs 
from surviving and proliferating (60, 61). On the other hand, a strong costimulatory 
molecule such as SA-4-1BBL that provides a potent secondary signal, generates an 
abundance of IL-2 and upregulates CD25 on Tconvs allowing them to break from 
suppression. Indeed, a recent study using an in vivo imaging approach has demonstrated 
that autoantigen-driven Treg clustering with Tconvs on the surface of DCs and 
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competition for IL-2 expressed by Tconvs is a major mechanism of autoimmune 
suppression (62). A similar IL-2 competition-based suppressive mechanism has recently 
been reported for NK cells (63).  
The present study demonstrating that SA-4-1BBL targets Tconvs directly for 
evasion of Treg suppression is in conflict with another study conducted with agonistic 4-
1BB antibody (64). The authors in the latter state that anti-4-1BB Ab impedes the 
suppressive function of Tregs by significantly downregulating the expression of IL-9 in 
these cells. They also demonstrate that the combination treatment with CpG-ODN 
adjuvant plus anti-IL-9 neutralizing antibody in vivo causes tumor rejection in the 
BALBneuT and MUC-1 models (64). However, this study did not provide direct 
evidence demonstrating that Tregs are the direct target of agonistic Abs to 4-1BB. The in 
vitro evasion of suppression data was obtained using Tconv:Treg cocultures similar to 
ours. Also, this study failed to demonstrate the direct role of IL-9 on Treg suppressive 
function in vitro. In contrast, our previous study using Tconvs and Tregs from wild type 
and 4-1BB KO mice provided direct evidence for Tconvs, but not Tregs, being the target 
of SA-4-1BBL for the observed evasion of suppression (36). 
 In conclusion, our findings that excessive production of IL-2 by Tconvs in 
response to SA-4-1BBL costimulation is both necessary and sufficient in overcoming 
Treg suppression may have significant implications for treatment of diseases associated 
with an imbalance between Tconvs and Tregs, such as cancer. High dose IL-2 
immunotherapy against tumors as well as low dose in combination with chemotherapy or 
IFN-α treatment has been the subject of several clinical studies since 1980s. The most 
pronounced effects were noticed in melanoma and renal cell carcinoma patients (65). The 
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toxicity caveat associated with the treatment regimen and administration of exogenous 
IL-2 has still yet to be overcome (66). SA-4-1BBL that safely drives the endogenous 
production of IL-2 from Teffs could serve as a great alternative without overdosing the 
system with excessive amounts of the cytokine.  
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CHAPTER 3: SA-4-1BBL AS AN IMMUNE ADJUVANT FOR THE GENERATION 





Previous studies in our laboratory have demonstrated that SA-4-1BBL as an 
adjuvant component of TAA-based subunit vaccine generates robust CD8
+
 T cell 
responses with therapeutic efficacy in various tumor models (27, 36). The SA component 
of the molecule is a bacterial antigen extracted from Streptomyces avidinii and has the 
potential to generate antibodies following repeated injections. The presence of anti-SA 
antibodies (Abs) may play a dual role by enhancing the efficacy of the vaccine through 
crosslinking the SA-4-1BBL molecules, hence leading to better receptor clustering and 
signaling. On the other hand, anti-SA Abs may bind and neutralize the effect of the SA-4-
1BBL molecule by blocking its interaction with 4-1BB or accelerating its in vivo 
clearance.   
In order to understand the positive or negative side effects of antibodies produced 
against vaccine immunogens, it is best to refer to studies concerning anti-drug antibodies 
(ADAs) against persistent biologics and protein treatments. For example, patients on 
adalimumab treatment for rheumatoid arthritis showed lower response rates in the 
presence of anti-adalimumab Abs, which directly correlated to lower levels of the 
adalimumab drug in their sera (67). Yet another study explored the effect of ADAs 
against infliximab, etanercept, adalimumab and ustekinumab in treated patients with 
psoriasis (68). The presence of anti-infliximab and anti- adalimumab Abs was associated 
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with lower serum drug concentrations, while anti-etanercept Abs had no apparent effect. 
Anti-ustekinumab antibodies played both positive and negative roles against psoriasis in 
separate studies. Therefore, a review of data shows that not all cases positive for ADAs 
have a loss of drug efficacy or cause hypersensitivity reactions. 
In this particular chapter, we explore the solo role of SA-4-1BBL costimulatory 
molecule and its impact on the immune system. The SA portion is a biological agent that 
carries several epitopes that can be recognized by T and B cells. In some studies it is 
suggested to reduce the immunogenicity of SA through the concomitant administration of 
methotrexate, or the use of mutated forms of the de-immunized protein with less 
antigenic epitopes, while maintaining tetramer forming and biotin binding capacities of 
the molecule (69, 70). Other studies exploit the use of immunogenic SA to the advantage 
of vaccine development and treatment.  For example, vaccination with soluble tumor 
proteins conjugated to SA has been shown to be effective in the 9L rat glioma model 
(71). In that study, antibodies against SA were detected in the immunized rats. However, 
Ab levels did not correlate with the anti-tumor response. Similarly, we show below that 
pre-treating mice with SA-4-1BBL protects against subsequent tumor challenges without 
interfering in post-tumor vaccine outcomes and without contribution from anti-SA 
antibodies. An insight into the mechanism of action of SA-4-1BBL and its role in anti-
tumor immunity is further demonstrated and discussed in this chapter.        
 










C57BL/6 mice were purchased from The Jackson Laboratory. C57BL/6.4-1BB knockout 
mice (40) and 4C mice (72) were bred and cared for in a University of Louisville specific 
pathogen-free animal facility in accordance with NIH guidelines. All animal procedures 
were approved by the University of Louisville’s IACUC.  
 
Antibodies and Reagents 
 
Antibodies used include anti-CD3 agonistic Ab (clone 145-2C11, BD Pharmingen, Cat# 
553058). Fluorescent-conjugated Abs to various cell surface markers were obtained 
commercially: anti-CD3-V500 (BD Horizon 560771); anti-CD4-Alexa700 (BD 
Pharmingen 557956); anti-CD8-APC-Cy7 (BD Pharmingen 557654); anti-NK1.1-PE 
(BD Pharmingen 553165); anti-CD19-APC (BD Pharmingen 550992); anti-CD44-APC 
(eBioscience 17-0441-83); anti-CD62L-PerCp-Cy5.5 (eBioscience 45-0621-82). Anti-4-
1BB agonistic Ab (clone 3H3) was produced and purified in our Lab. 500 µg/mouse of 
depletion antibodies were injected i.p. in specified experiments including anti-CD4 Ab 
(clone GK1.5); anti-NK1.1 Ab (clone PK 136); anti-CD8 Ab (clone 53.6.72); and anti-
CD20 Ab 200 µg/mouse (clone 5D2). 
SA-4-1BBL and SA proteins were produced in our lab according to standard protocols as 
previously reported (34, 41, 42). TC-1 tumor cell line was obtained from American Type 








Immunization strategy and tumor challenge 
 
Several groups of mice were challenged subcutaneously (s.c.) with 2 shots of SA-4-1BBL 
(25 µg) on days 0 and 14. Unless specified, mice were injected two weeks later s.c. with 
1 x 10
5 
cells of TC-1 tumor cell line. TC-1 is originally derived from lung epithelial cells 
of C57BL/6 mice and transfected to express the human papillomavirus HPV-E6 and E7 
proteins. In certain groups, mice also received post tumor challenge vaccination with 50 
µg E7-P1 peptide (RAHYNIVTF) + 25 µg SA-4-1BBL (Fig. 14). Tumors were 
monitored and measured twice a week using calipers over a period of 60 days or until 
tumor average diameter reaches its endpoint (12 mm). In select experiments, Lewis Lung 
Carcinoma (LLC) cell line was used instead of TC-1. For long term memory studies, 
tumor free mice at the experimental endpoint were re-challenged with 1 x 10
5 
cells of TC-
1 and monitored for at least additional 60 days.  
 
Enzyme-linked immunosorbent assay (ELISA) for serum antibodies and subtyping 
 
Blood was collected and serum isolated from different groups of mice 1 week after the 
2
nd
 immunization with SA-4-1BBL and at experimental end points. ELISA plates were 
coated overnight with 50 ng of either SA-4-1BBL or SA proteins. Next day plates were 
washed, blocked with milk, and incubated with serial dilutions of specified sera for 1.5 
hours at room temperature. After that, secondary antibodies conjugated to horseradish 
peroxidase enzyme (HRP) were added for 1 hour to measure for total IgG titers as well as 
several isotypes including IgG1, IgG2b, IgG2c, IgG3, IgM, and IgA. Plates were 
incubated for 30 min with TMB substrate (BD Biosciences, Cat#555214), reaction was 




Adoptive serum transfer 
 
Sera collected on Day 27 from SA-4-1BBL-immunized mice (25 µg on days 0 and 14 
s.c.) were adoptively transferred to naïve C57BL/6 mice (200 µl i.v.) 24 hours prior to 
TC-1 tumor challenge (1 x 10
5
 cells s.c.). Sera antibody titers were tested by ELISA 
against SA prior to transfer. Tumor diameters were measured twice a week using calipers 
over a period of 60 days or until tumor average diameter reaches its endpoint (12 mm).  
 
Anti-CD3 proliferation assay 
 




were cultured in 96-well U-bottom plates and 
stimulated with anti-CD3 agonistic antibody (0.025 µg/ml) and serially diluted doses of 
SA-4-1BBL in the presence or absence of mice serum pre-immunized twice with 25 µg 
of SA-4-1BBL. Cultures were incubated for 48 h and pulsed with [
3
H]-thymidine for an 
additional 16 h. Plates were harvested with Tomtec Cell Harvester and proliferative 
counts were measured with a Beta plate counter and reported as CPM. 
 
Flow cytometry and phenotyping 
 
Spleens and draining lymph nodes from naïve, 12.5 µg SA + 100 µg 3H3 immunized, or 
25 µg SA-4-1BBL immunized C57BL/6 mice were harvested at different time points and 
processed into single cell suspensions. One million cells of each sample were stained 
with fluorescent-conjugated antibodies with corresponding compensation and isotype 
controls for flow cytometry. CD4
+
 T cells and CD8
+
 T cells were gated on CD3
+
 
population. B cells were gated on CD19
+









. Cell percentages as well as absolute cell 



















At experimental end points, Kaplan-Meier survival curves were graphed and log-rank 
statistical method was applied between groups using GraphPad software, with p ≤ 0.05 




Streptavidin portion of SA-4-1BBL is immunogenic  
 
To assess the immunogenicity of SA-4-1BBL, a group of C57BL/6 mice (Group 
1) was immunized twice with 25 µg of SA-4-1BBL via s.c. injection on days 0 and 14. 
Blood was withdrawn and isolated serum was tested by ELISA for humoral responses 
one week before TC-1 tumor challenge, one week after tumor challenge, and at 
experimental endpoint (Fig. 14). ELISA plates pre-coated with SA-4-1BBL (Fig. 15) or 
SA (data not shown) had comparable total IgG titers. Serum antibody titers were positive 
on day 21 (4 out of 5 animals), slightly elevated on day 34 (5 out of 5), then slightly 
reduced on day 90 (Fig. 15). A second group of mice (Group 2) was treated with the 
same regimen, except that this group also received a subunit vaccine consisting of a 
peptide (P1) representing the dominant CD8
+
 T cell epitope for HPV E7 antigen and SA-
4-1BBL on day 36. Antibody titers were tested positive on day 21 (2 out of 5 animals), 
elevated on day 34 (5 out of 5), then slightly reduced on day 90 (Fig. 15).  
We next subtyped the Abs to assess the nature of immune responses generated. 
IgG1 isotype is usually indicative of Th2 responses while IgG2a is associated with Th1 
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responses (73). IgM is mainly upregulated during primary immune responses and 
undergoes class switching during secondary responses. T-helper independent antibody 
production on the other hand favors the IgG3 subtype. Subtyping ELISA for group 1 on 
days 21 and 90 (Fig. 16) revealed IgG1 and IgM to be the major isotypes upregulated 
upon SA-4-1BBL immunization. 
The positive humoral immune response led us to test if SA also generates CD4
+
 T 
cell responses. Mice were immunized once with SA-4-1BBL. Seven days later spleens 
from naïve as well as immunized mice were harvested, processed, and cultured in vitro 
for 48 hours in the presence or absence of SA stimulation. Cultures were pulsed with 
3
[H]-thymidine for additional 16 hours and CPMs were recorded. SA was capable of 
generating more than 3 fold T cell proliferative responses in SA-4-1BBL immunized 
cultures as compared to naïve background (Fig. 17). 
 
Anti-SA Abs do not negatively impact the costimulatory function of SA-4-1BBL in 
vitro and in vivo 
 
 To test if anti-SA antibodies hinder or augment the costimulatory function of the 
SA-4-1BBL molecule, we conducted an in vitro proliferation assay with SA-4-1BBL 
costimulation-driven expansion of T cells as a read out. In brief, naïve C57BL/6 
splenocytes were stimulated with the agonistic anti-CD3 Ab in the presence of SA-4-
1BBL incubated with naïve (set 1) or pre-immunized (set 2) serum (Fig. 18). The pre-
immunized serum containing anti-SA antibodies did not alter the ability of SA-4-1BBL to 
deliver its costimulatory signal, as set 2 splenocytes proliferated as efficiently as set 1 in 
vitro.     
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Following the experimental design demonstrated in Figure 14, we assessed if the 
in vivo-generated anti-SA antibodies, produced by repeated injections with SA-4-1BBL, 
might modify the post-tumor vaccination outcome with the E7 peptide-based vaccine in 
the transplantable TC-1 tumor model. As depicted in the survival curve in Figure 19, 
administering SA-4-1BBL twice not only left the post-tumor vaccine efficacy intact, but 
also induced 100% tumor protection by itself up to 70 days after tumor challenge. 
 
Pretreatment with SA-4-1BBL generates a prolonged window of immune responses 
against TC-1 tumor 
 
In order to understand the dynamics of the SA-4-1BBL anti-tumor immune 
response observed in Figure 19, we next performed extensive time-course pre-
immunization studies in C57BL/6 mice receiving TC-1 tumors at different time points 
after prime or prime/boost immunizations with SA-4-1BBL. As shown in Fig. 20A and 
20B, 1 shot of SA-4-1BBL, 1 day later or 1 week later TC-1 challenge protocols did not 
confer any tumor protectivity, suggesting that immediate innate immune response alone 
is not sufficient. On the other hand, administering TC-1 two weeks after SA-4-1BBL 
immunization, showed around 40% survival (Fig. 20C), which provides enough time for 
adaptive immunity to kick in. 
In a second set of studies, we observed 40% survival with 2 shots of SA-4-1BBL, 
1 day later TC-1 challenge (Fig. 21A); 100% survival with 2 shots of SA-4-1BBL, 1 
week later TC-1 (Fig. 21B); 100% survival and 80% survival were recorded with 2 shots 
of SA-4-1BBL, 4 weeks and 8 weeks later TC-1 injection respectively (Fig. 22A); but we 
noticed a significant drop in survival for the 2 shots SA-4-1BBL, 12 weeks later TC-1 
challenged group (Fig. 22B).  
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SA-4-1BBL generates long-term immune memory against TC-1 
 
Our study design to test for protection against TC-1 recurrences was as follows: 
naïve C57BL/6 mice were immunized twice with SA-4-1BBL (2 weeks apart), followed 
by 1
st
 TC-1 tumor cells challenge 2 weeks after the second immunization. Mice were 
monitored for a period of 60 days after 1
st
 tumor injection. At the end of the 60 days, 
tumor free mice were rechallenged with a 2
nd
 shot of TC-1 tumor cells and monitored for 
another 80 days (Fig. 23). As shown, pre-immunization with SA-4-1BBL alone 
significantly delayed the onset and growth rate of tumors after 2
nd
 TC-1 challenge, hence 
establishing a long term memory effect. Pre-immunization + post-tumor vaccination 
group establishes a different type of memory that is specifically directed towards E7-P1 
tumor antigen and is mediated through IFN-γ and CD8 cells (27) where we clearly obtain 
60% survival even after 80 days from 2
nd
 tumor challenge (Fig. 23).   
 Phenotyping of spleens (spls) and draining lymph nodes (dLNs) for the SA-4-
1BBL pre-immunized group 60 days post-tumor injection revealed a significant increase 
in the CD4
+
 T effector memory compartment both in spls and dLNs.  In addition, the 
CD4
+
 T central memory compartment was elevated in the draining lymph nodes of these 
mice (Fig. 24).   
The protective effect of pretreatment with SA-4-1BBL is tumor-type independent  
 
 We hypothesized that since the SA-4-1BBL-generated immune response was 
independent from tumor specific antigens, then the type of the transplantable tumor used 
would not affect the outcome. To test this, C57BL/6 mice were immunized twice with 25 
µg SA-4-1BBL (2 weeks apart), followed by Lewis Lung Carcinoma (LLC) or TC-1 
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tumor challenge 2 weeks after the 2
nd
 immunization. Indeed, pre-immunization with SA-
4-1BBL alone showed significant protection against LLC relative to TC-1 (Fig. 25).   
 
Anti-SA Abs do not play a role in the protective effect of pretreatment with SA-4-
1BBL against TC-1 tumor 
 
Humoral immunity has been shown to play a role in the efficacy of various cancer 
immunotherapies. Antibodies can have a direct effect on the tumor by recognizing and 
binding to surface antigens, or by helping antigen-presentation and processing by APCs 
through opsonization, thereby augmenting downstream adaptive immune responses. 
Given the positive titers of SA-Abs in the pretreatment setting, we asked if such Abs can 
contribute to the protective effect we observe against TC-1 tumors. Towards this goal, 
sera were collected on day 27 from SA-4-1BBL immunized mice (25µg on days 0 and 
14) and adoptively transferred into naïve C57BL/6 mice (200 µl/mouse) 24 hours prior to 
TC-1 tumor challenge. Anti-SA Abs in adoptively transferred sera did not show any 
significant protection and all the recipient mice expired similar to TC-1 control (Fig. 26). 
 
Protective effect of SA-4-1BBL against tumor involves a cross-talk between NK and 
CD4
+
 T cells  
 
The lack of a positive effect of anti-SA Abs on tumor protection led us to 
hypothesize that protection involves cellular immunity. In search for target effector cells, 
and in the light of our previous findings about the role of NK cells in tumor protection 
(27), we conducted 2 sets of NK depletion studies with reference to Figure 14 design. In 
the first set, NK cells were depleted with anti-mouse NK1.1 Ab 1 day prior to each 
immunization with SA-4-1BBL (days -1 and 13). In the second set, NK cells were 
depleted once 1 day before TC-1 tumor challenge (day 27). Mice were monitored for 
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additional 60 days after tumor injection and survival assessed at the experimental 
endpoints (Fig. 27). In both sets of experiments, depletion of NK cells significantly 
compromised SA-4-1BBL efficacy against TC-1 tumors.  
In the same fashion, CD4 cells were depleted using anti-CD4 Ab during 2 distinct 
phases. The initiation phase covers the first 27 days before TC-1 challenge where CD4 
cells were depleted 1 day prior to immunizations with SA-4-1BBL (Fig. 28), and the 
effector phase covers the 60 day period after TC-1 challenge where CD4 cells were 
depleted 1 day before TC-1 injection (Fig. 29). In both phases, the presence of CD4 cells 
was critical in driving and maintaining the SA-4-1BBL-mediated anti-tumor effect. 
Surprisingly, depletion of CD8 cells 1 day prior to SA-4-1BBL immunizations did not 
abrogate the anti-tumor effect (Fig. 28). 
In order to discount any role of B cells or contribution from antibodies in the 
observed SA-4-1BBL-mediated anti-tumor immunity, we depleted B cells with an anti-
CD20 antibody during the initiation phase (1 day before SA-4-1BBL immunizations). In 
the absence of B cells, SA-4-1BBL still induced 100% survival against TC-1 (Fig. 30), 
showing the lack of dependence on B cells and anti-SA antibodies.      
 
CD4 cells should recognize SA for optimal anti-tumor protectivity 
 
 To further confirm the importance of the CD4
+
 T cell responses to the observed 
protective effect of SA-4-1BBL pretreatment, we used the 4C T-cell receptor transgenic 
mice where 99% of the CD4 T cells express the vβ13 chain and exclusively recognize 
allogeneic Balb/c MHC class II antigen. Due to this specificity, these mice should not 
recognize SA upon SA-4-1BBL immunization. Indeed, pre-immunization with SA-4-
1BBL was futile in these mice and tumor protectivity against TC-1 was lost (Fig. 31), 
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although we noticed a non-significant delay in tumors expiration as compared to 4C 
controls injected with TC-1 alone. We also noticed attenuated T cell proliferation in 4C 
mice first immunized with SA-4-1BBL for 7 days, followed by stimulation in vitro with 
SA antigen, as compared to wild type C57BL/6 mice (Fig. 32). On the other hand, this 
minimal recognition of SA in 4C mice was sufficient to generate anti-SA antibodies (Fig. 
33), which further confirmed our previous observation that antibodies themselves are not 
protective, as all mice expired from tumor burden. Sera collected from SA-4-1BBL-
immunized 4C mice was subjected to subtyping ELISA resulting in detection of high 
levels of IgM and IgG1 isotypes and low levels of IgG2b and IgG2c as compared to 
immunized B6 control (Fig. 34).  
 
The anti-tumor effect of SA-4-1BBL is a unique property of this molecule and is not 
achieved using agonistic Ab to the receptor 
 
We have previously shown qualitative and quantitative difference between SA-
41BBL and agonistic Ab to 4-1BB (23). We therefore tested if the anti-tumor protection 
of SA-4-1BBL is a unique property of this molecule or it can be extended to any agonist 
of 4-1BB receptor. Different groups of C57BL/6 mice were immunized twice with either 
SA alone (12.5 µg), 3H3 alone (100 µg), SA + 3H3, or SA-4-1BBL (25 µg), followed by 
TC-1 challenge 2 weeks after the 2
nd
 immunization. Pre-immunization with 3H3 alone, 
SA alone, or with SA + 3H3 did not result in any tumor protection compared to the TC-1 
control group (Fig. 35). On the other hand, pre-immunization with SA-4-1BBL has 
demonstrated a unique attribute in rejecting subsequently challenged tumors by reaching 
80 to 100% survival.     
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 Lymphocyte percentages and absolute cell number analysis in spleens of mice 
immunized twice with SA + 3H3 vs. SA-4-1BBL showed a significant reduction in NK 
cells in the SA + 3H3 group (Figs. 36, 37). This could be a direct effect of 3H3 on NK 
cells since they express the 4-1BB receptor, or it could be the result of 3H3 blocking the 
function of a helper cell population providing assistance to NK cells such as CD4
+
 T 
cells. On the other hand, analysis of draining lymph nodes of the immunized mice 
showed reduced percentages of NK cells but not absolute cell numbers in the SA + 3H3 
treated group (Figs. 38, 39). This observation could be attributed to the toxicity and 
lymphadenopathy associated with 3H3 treatment, since the lymph nodes harvested were 
significantly larger in size and had greater total cell counts as compared to the SA-4-
1BBL treated group (data not shown).     
Moreover, we noticed a shutdown in anti-SA antibody production in the group 
immunized with SA + 3H3 twice (Fig. 40). Sera was collected on day 21 (1 week after 
2
nd
 immunization) and at tumor endpoints, and was subjected to ELISA. We have 
previously demonstrated in this chapter that the lack of anti-SA antibodies has no effect 
on tumor rejection, which suggests a direct negative role of 3H3 on CD4
+













Our hypothesis was that, since SA portion of SA-4-1BBL is a foreign bacterial 
antigen, repeated immunizations with SA-4-1BBL might generate desirable or non-
desirable immune responses affecting the overall efficacy of the therapeutic anti-tumor 
vaccine. Indeed, immunizations with SA-4-1BBL generated anti-SA antibodies detected 
in mice sera over a period of 90 days. We initially thought that these antibodies might be 
able to activate NK cells through antibody-mediated cell cytotoxicity (ADCC) leading to 
tumor eradication. Ideally, for that to take place the tumors should express SA antigen. 
Upon testing TC-1 tumor lysates by Western blotting, SA protein was not detected (data 
not shown), although we cannot exclude the possibility of cross-reactivity occurring with 
another tumor-associated protein that resembles SA. Antibodies on the other hand may 
also play a negative role, since they may be recruited by the tumor to mask itself and 
evade immunity. Anti-SA antibodies may also potentially bind to the SA-4-1BBL 
molecule hindering its efficacy or neutralizing its effect. Our data here show that anti-SA 
Abs do not have an effect on the costimulatory function of the SA-4-1BBL molecule 
either in vitro or in vivo.  
Based on our previous work, vaccination with E7 + SA-4-1BBL had ~70% 
therapeutic efficacy in the TC-1 model (27). Therefore, the observed 100% therapeutic 
efficacy against TC-1 tumor with the subunit vaccine in the SA-4-1BBL pretreatment 
setting was surprising (Fig. 19), and led us to further test the immune responses generated 
with SA-4-1BBL treatment alone. One shot of SA-4-1BBL, one day or one week later 
TC-1 challenge, did not show any anti-tumor effect suggesting that initial innate immune 
responses alone are not sufficient. Two shots of SA-4-1BBL treatment regimen, followed 
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by TC-1 challenge one, two, four, or eight weeks afterwards showed full anti-tumor 
protection. This prolonged SA-4-1BBL effect suggests the involvement of adaptive 
immunity which can further sustain innate immune activity.   
Mechanistic studies aiming at identifying effector immune cells involved in the 
observed SA-4-1BBL protection were conducted. Inasmuch as our previous studies have 
demonstrated the critical role of CD8
+
 T cells in vaccine efficacy (26), we depleted these 
cells one day before pretreatments with SA-4-1BBL followed by TC-1 tumor challenge 
after two weeks. Immunized mice suppressed tumor growth, discounting the potential 
involvement of CD8 cells. The interplay between NK cells and CD4 cells was proven 
critical for maintaining a prolonged effect against tumors as shown by the depletion 
studies. During the initiation phase, SA-4-1BBL may be acting on NK cells that express 
4-1BB receptor on their cell surface (28), CD4
+
 T conventional cells, or on both cell 
types simultaneously. After tumor challenge and during effector phase, the presence of 
CD4 cells proved essential for maintaining the anti-tumor effect observed. In addition to 
that, SA-4-1BBL’s effect was not directed towards B cells, as depletion of such cells 
before immunizations did not interfere in protection from tumor. The later observation 
further confirmed that anti-SA antibodies generated by plasma cells do not play a role. 
Adoptive serum transfer of SA-4-1BBL-immunized sera to naïve mice prior to tumor 
challenge strongly suggests a lack of antibody protectivity.          
Our data indicate that pretreatment of mice with SA-4-1BBL chimeric protein 
establishes a communication bridge between NK and CD4
+
 T cells. To further test the 
hypothesis, we used 4C TCR transgenic mice pre-immunized twice with SA-4-1BBL 
prior to TC-1 tumor challenge. CD4
+
 T cells in these mice did not recognize, or at least 
44 
 
did not optimally recognize SA as antigen; hence all mice expired due to tumor burden 
despite the presence of NK cells and treatment with SA-4-1BBL. It is important here to 
recall that 4-1BB expression on CD4
+
 T cells is inducible and requires an initial signal, 
apparently provided by SA in this case, to be upregulated and to deliver effective 
costimulatory signals. The importance of CD4
+
 T cells shown here is in agreement with 
our therapeutic vaccine data published earlier emphasizing the effect of SA-4-1BBL on 
CD4
+
 T cells (25). Depletion of CD4 cells one day before tumor challenge resulted in 
compromised vaccine efficacy delivered after six days, and depletion of CD4 cells one 
day before vaccine led to loss of long-term immunological memory against Lewis lung 
carcinoma (25). 
Several studies in the literature suggest IL-2 cytokine to be fundamental for CD4-
NK communication in overcoming tumors and fighting infectious microbes. HIV-1 viral 
infection provides a good example, where CD4
+
 T cell numbers are compromised along 
with their IL-2 production, leading to NK cells anergy and irresponsiveness to infection 
(74). In the same study, subjects immunized with HIV-1 subunit vaccine showed 
increased IL-2 production by Gp120-specific CD4
+
 T cells associated with higher IFN-γ 
levels produced by NK cells (74). In another study conducted in CD8 α-chain KO mice, 
collaboration between CD4
+
 T cells and NK cells was critical in fighting B16 melanoma 
tumors upon delivery of non-antigen-loaded immature dendritic cell vaccine (75). 
Another clinically relevant report demonstrated that CD56
bright
 NK cells isolated from 
human subjects constitutively express the high-affinity IL-2 receptor. These NK cells 
produced higher levels of IFN-γ when cocultured with CD4+ T cells producing IL-2 
cytokine upon activation with tetanus toxoid (76). Moreover, human NK cells activated 
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by IL-2 and NKG2D receptor or CD16 were shown to upregulate OX40L expression on 
their surface, costimulating CD4
+
 T cells expressing OX40 to produce IFN-γ (77). In the 
dLNs of mice newly infected with Leishmania major parasite, CD4
+
 T cells were shown 
to directly activate NK cells through the production of IL-2 or indirectly through the 
regulation of IL-12 secretion by dendritic cells (78). The cross-talk between innate and 
adaptive immunity through IL-2 was also emphasized in a malaria infection setting with 
special focus on NK and CD4
+
 T cells interacting together in an MHC class II-dependent 







 T cells (17), capable of producing granzymes and 
fighting melanoma cells, don’t seem to be involved in SA-4-1BBL’s anti-tumor effect. 
While conducting our pre-immunization mechanistic studies, we depleted NK cells 1 day 
before TC-1 while leaving CD4 cells intact and subject to activation by SA-4-1BBL. 
Regardless of the presence of any killer CD4
+
 T cells during priming and effector phases, 
the lack of NK cells voided SA-4-1BBL’s effect and all mice expired.    
 In this study we recognized and established the unique anti-tumor property of the 
SA-4-1BBL molecule, not achieved otherwise using agonistic Ab to the receptor. In our 
hands, anti-tumor protection was lost when mice were immunized with SA + 3H3. We 
also observed the shutdown of antibody production against SA in the presence of 3H3. 
Our observation is in accordance with published literature suggesting that monoclonal 
agonistic antibodies against 4-1BB can block antibody production by B cells, a method 
used in the treatment of autoimmune diseases such as Systemic Lupus Erythematosus 
(SLE) and Graft-versus-host disease (GVHD) (80, 81). The mechanism seems to be 
mediated by inducing anergy of helper T cells, which in turn cease to provide help to B 
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cells, halting their antibody production (82). Moreover, we have also noticed a reduction 
in the percentages and absolute cell numbers of NK cells in mice pretreated with SA + 
3H3, but not SA-4-1BBL. This may be due to the indirect deleterious effect of 3H3 on 
CD4
+
 T helper functions, or it may be due to direct engagement of 3H3 with its receptor 
on NK cells. The effect of agonistic antibodies to 4-1BB on NK cells is controversial in 
the literature. Some of the studies reporting positive aspects include human NK cells 
activated by trastuzumab in breast cancer treatment which upregulated 4-1BB, and 
further stimulation with anti-4-1BB Ab killed breast cancer cells (83). Similarly, the anti-
lymphoma activity of rituximab was improved by stimulation of NK cells with anti-4-
1BB monoclonal antibody (84). Others also reported regulatory aspects of NK cells in 
anti-tumor settings without having cytolytic activity (85). In that study, CD137-
stimulated helper NK cells successfully proliferated and produced IFN-γ to augment 
CD8
+
 cytotoxic T lymphocytes, but did not directly kill p815 mastocytoma tumor cells. 
On the other hand, several studies report the negative role of anti-4-1BB stimulation on 
NK cells including toxicity and excessive systemic inflammation in mice and humans 
(15, 23). Overproduction of IFN-gamma by CD8
+
 T cells and NK cells upon stimulation 
with anti-4-1BB Ab was shown to downregulate the frequency and number of NK cells in 
the spleens and bone marrows of tumor-bearing mice. NK numbers were otherwise 
restored in 4-1BB knockout mice (86). 
In conclusion, our data collectively confirm SA-4-1BBL to be a bona fide 
immune modulator possessing anti-tumor properties, successfully bridging innate and 
adaptive immunities with vast clinical applications. SA-4-1BBL immunotherapy provides 
a better and safer alternative for clinically applied agonistic TNFR antibodies, and/or 
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standard treatment regimens such as chemotherapy or radiotherapy that bear several side 
effects. Deciphering the detailed mechanism(s) of communication between CD4
+
 T cells, 
NK cells, and other accessory immune cells in pre-clinical settings, will definitely help in 
future development of preventative as well as therapeutic anti-tumor vaccines. Towards 
that end, our future experiments will aim at monitoring and studying the nature and levels 
of cytokines produced upon SA-4-1BBL versus 3H3 and SA + 3H3 pre-immunizations as 
well as the cellular phenotypes associated (successfully activated and functional versus 
anergic and irresponsive). We will also explore the possibility of combining innate 
immune adjuvants such as monophosphoryl lipid A (MPL) and/or other TNF 
costimulatory molecules such as OX40L with SA-4-1BBL in pre-immunization settings 
in order to reach ultimate preventative anti-tumor protection with prolongation in 










Figure 1. Costimulation by SA-4-1BBL overcomes suppression of Tconvs by Tregs 
independent of APCs. Flow-sorted Tconvs were cocultured with freshly sorted or 
expanded Tregs at 1:1 ratio in the presence of irradiated splenocytes from wild type or 4-
1BB
-/-
 mice as APCs and anti-CD3 Ab (0.5 µg/ml). SA-4-1BBL (1 µg/ml) was added to 
cultures where indicated. Cultures were incubated for 48 h, pulsed with [
3
H]-thymidine 
for an additional 16 h, and proliferation was measured and graphed as cpm. Each data 
point is indicative of mean ± SEM of triplicate wells and representative of 2 separate 
experiments. Student’s t-test (two-tailed) was performed for statistical analysis with *p ≤ 







Tconv + - + + + + + + + +
Treg - + - - - - + + + +
WT APC - - + + - - + + - -
4-1BB-/-APC - - - - + + - - + +

















Figure 2. Costimulation by SA-4-1BBL overcomes suppression of Tregs to Tconvs in 
absence of APCs. Suppression assay was conducted with sorted Tconvs and Tregs 
without APCs using plate bound anti-CD3 Ab (5 µg/ml) and soluble SA-4-1BBL (1 
µg/ml) where indicated. Each data point is indicative of mean ± SEM of triplicate wells 
and representative of 2 separate experiments. Student’s t-test (two-tailed) was performed 

























Figure 3. TGF-β cytokine is not involved in Tconv evasion of Treg suppression. Sorted 
Tconvs and Tregs were cocultured at 1:1 ratio in the presence of irradiated APCs and 
anti-CD3 Ab (0.5 µg/ml). Cultures were also supplied with SA-4-1BBL (1 µg/ml) and 
blocking Ab to TGF- (either 8 or 50 µg/ml) at the time of incubation. Each data point is 
indicative of mean ± SEM of triplicate wells and representative of 2 independent 
experiments. Student’s t-test (two-tailed) was performed for statistical analysis with *p ≤ 
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Figure 4. Cell surface-bound TGF-β is not involved in Tconv evasion of Treg 
suppression. Sorted Tconvs and Tregs were cocultured at 1:1 ratio in the presence of 
irradiated APCs and anti-CD3 Ab (0.5 µg/ml). Cultures were supplemented with Tregs 
pre-incubated with anti-TGF-β Ab (50 µg/ml), then stimulated with SA-4-1BBL (1 
µg/ml) wherever indicated. Each data point is indicative of mean ± SEM of triplicate 
wells and representative of 2 independent experiments. Student’s t-test (two-tailed) was 
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Figure 5. IFN-γ cytokine is not involved in Tconv evasion of Treg suppression. Sorted 
Tconvs and Tregs were cocultured at 1:1 ratio in the presence of irradiated APCs and 
anti-CD3 Ab (0.5 µg/ml). Cultures were also supplied with SA-4-1BBL (1 µg/ml) and 
anti-IFN- blocking antibody (25 µg/ml). Each data point is indicative of mean ± SEM of 
triplicate wells and representative of 2 independent experiments. Student’s t-test (two-
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Figure 6. IL-2 is a predominant cytokine upregulated in Tconv and Tregs cocultures 
costimulated with SA-4-1BBL. Sorted Tconvs and Tregs were cocultured at 1:1 ratio and 
48 h later supernatants were collected and subjected to cytometric bead array analysis. 
Cultures contain irradiated APCs, SA-4-1BBL (1 µg/ml) as shown, and soluble anti-CD3 
Ab (0.5 µg/ml). Data shown is combination of two independent experiments with mean ± 
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Figure 7. IL-2 is the predominant cytokine upregulated in Tconv and Tregs cocultures 
costimulated with SA-4-1BBL without APCs. Sorted Tconvs and Tregs were cocultured 
at 1:1 ratio and 48 h later supernatants were collected and subjected to cytometric bead 
array analysis. Cultures were stimulated with plate bound anti-CD3 Ab (5 µg/ml) and 
SA-4-1BBL (1 µg/ml) as indicated. Data shown is combination of two independent 
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Figure 8. RT-PCR ∆∆CT values for relative IL-2 mRNA expression with respect to 
GAPDH gene in indicated cultures stimulated with SA-4-1BBL (1 µg/ml) and plate-
bound anti-CD3 Ab (5 µg/ml). IL-2 expression was assessed at 24 (A) and 48 (B) hours 
post-stimulation. Each data point represents the mean of triplicate wells ± SD, with *p ≤ 


























































Figure 9. Removal of SA-4-1BBL from Tconv culture supernatants. Supernatant (sup) of 
Tconvs stimulated with an agonistic anti-CD3 Ab (5 µg/ml) and SA-4-1BBL (1 µg/ml) 
were incubated with CuSO4-charged sepharose beads to remove SA-4-1BBL carrying a 
6xHis tag. Regular sup (batch 1) and SA-4-1BBL-depleted sup (batch 2) were analyzed 
using anti-SA antibodies for detection in Western blots. The indicated amounts of SA-4-




















Figure 10. Removal of IL-2 from Tconv culture supernatants. Batch 2 supernatant, 
cleaned from SA-4-1BBL as described in Figure 9, was incubated with an anti-IL-2 Ab 
(20 µg/ml) followed by the removal of Ab/IL-2 complexes using immobilized protein G 
beads to generate batch 3. Batch 2 as well as batch 3 supernatants (50 µl/each) were 
tested on the IL-2-dependent CTTL-2 cell line with the indicated commercial 
recombinant IL-2 doses (IU/ml) as positive and PBS as negative controls. Cultures were 
incubated for 28 h with [
3
H]-thymidine added for the last 8 h. Proliferation was measured 
and graphed as cpm. Each data point is indicative of mean ± SEM of triplicate wells. 
Student’s t-test (two-tailed) was performed for statistical analysis with *p ≤ 0.05 being 
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Figure 11. SA-4-1BBL costimulation-mediated IL-2 production by Tconvs is both 
necessary and sufficient in overcoming Treg suppression. Sorted Tconvs and Tregs were 
cocultured at 1:1 ratio in the presence (A) or absence (B) of irradiated APCs and anti-
CD3 Ab. Cultures were also supplemented with SA-4-1BBL (1 µg/ml), IL-2 (3 IU/ml), 
SA-4-1BBL-depleted supernatants (100 µl/well), or SA-4-1BBL- and IL-2-depleted 
supernatants (100 µl/well) where indicated. Each data point is indicative of mean ± SEM 
of triplicate wells. Student’s t-test (two-tailed) was performed for statistical analysis with 
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Figure 12. Tconvs proliferate to a higher extent upon SA-4-1BBL stimulation as 
compared to Tregs. Tconvs sorted from WT C57BL/6 or Tregs sorted from 
C57BL/6.Foxp3
hCD2 
mice were labeled with 2.5µM CFSE and used in coculture 
suppression assays with irradiated APCs. Cultures were incubated for 64 h and cells were 




























Figure 13. IL-2-mediated Tconvs evasion of Tregs suppression is independent of Tregs 
proliferative state. Sorted Tconvs and Tregs were cocultured at 1:1 ratio in the presence 
of APCs and anti-CD3 Ab (0.5 µg/ml). Cultures were also supplemented with SA-4-
1BBL (1 µg/ml) or IL-2 (3 IU/ml) wherever indicated. In select cultures, Tregs were 
irradiated at 2000 cGy (Tregs*) prior use. Each data point is indicative of mean ± SEM of 
triplicate wells. Student’s t-test (two-tailed) was performed for statistical analysis with *p 



































Figure 14. Schematic time line to study SA-4-1BBL’s immunogenicity. C57BL/6 mice 
were immunized twice with 25 µg of SA-4-1BBL s.c. on days 0 and 14, followed by TC-
1 tumor challenge (1 x 10
5
) s.c. two weeks after the second immunization. Post-tumor 
vaccination (50 µg E7-P1 peptide + 25 µg SA-4-1BBL) was administered s.c. 8 days 
after tumor challenge. Mice were monitored for a period of 60 days after tumor injection 
and measurements were taken twice a week using calipers. Mice were euthanized when 
average tumor size ≥ 12 mm or on day 60 post tumor challenge to be considered the 
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Figure 15. Anti-SA antibodies generated in vivo upon SA-4-1BBL immunization. ELISA 
plates were coated overnight with 50 ng of SA-4-1BBL protein. Next day plates were 
washed and incubated with serial dilutions of specified sera for 1.5 hours, after which 
goat-anti-mouse secondary antibody conjugated to HRP was added for 1 hour. 
Colorimetric reaction was generated using TMB substrate for 30 minutes and plates were 




























Figure 16. Subtyping serum ELISA for pre-immunization group on days 21 and 90. 
ELISA plates pre-coated with 100 ng of SA-4-1BBL overnight. 1/25 dilution of positive 
sera is used the next day to test the IgG1, IgG2a, IgG2b, IgG3, IgM, IgA, and IgG2c 































































Figure 17. SA is immunogenic and drives the proliferation of T cells in vitro. Two naïve 
and four immunized C57BL/6 mice with 1 shot of SA-4-1BBL (25 µg s.c.) were used. 
Seven days later, spleens were harvested, processed, and cultured in vitro for 48 hours in 
the presence or absence of SA stimulation (5 µg/ml). Cultures were pulsed with 
3
[H]-
thymidine for additional 16 hours and CPMs were recorded. Each data point represents 
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Figure 18. Anti-SA antibodies generated in vivo do not help the in vitro proliferative 
function of SA-4-1BBL molecule. Sera were collected on day 21 from SA-4-1BBL pre-
immunized C57BL/6 mice (25µg on days 0 and 14 s.c.). SA-4-1BBL at different doses 
(µg/ml) was incubated in vitro with naïve or experimental sera (log10 = 2.8) for 1 hour at 
room temperature prior addition to splenocytes stimulated with agonistic anti-CD3 (0.025 
µg/ml). Cultures were incubated for 48 hours at 37
o
 / 5% CO2 followed by additional 16 
hours with 
3
[H]-thymidine. Plates were harvested and counts were recorded as CPM. 
Each data point represents the mean ± SEM of triplicate wells. Experiment was repeated 
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Figure 19. Pre-immunization with SA-4-1BBL does not alter the post-tumor vaccination 
outcome, but scores 100% survival against TC-1 tumors. Naïve C57BL/6 mice were 
immunized twice with 25 µg SA-4-1BBL (days 0 and 14 s.c.). Two weeks later (day 28) 
mice were challenged with TC-1 tumors (1 x 10
5 
cells s.c.). On day 36, the pre-
immunization + post vaccination group received a post-tumor vaccine challenge (50 µg 
E7-P1 peptide + 25 µg SA-4-1BBL s.c.). Mice were monitored for 70 days post tumor 
injection as shown above. Tumors were measured twice a week using calipers. Mice were 
euthanized when average tumor diameters had reached ≥ 12 mm or when experimental 



































Figure 20. Time-course pre-immunization studies with 1 shot SA-4-1BBL against TC-1. 
C57BL/6 mice were immunized with 1 shot SA-4-1BBL (25 µg s.c.) followed by TC-1 
challenge (1 x 10
5 
cells s.c.) 1 day (A), 1 week (B), or 2 weeks (C) after immunization. 
Tumor measurements were recorded twice a week using calipers and mice were 
euthanized when tumor average diameter ≥ 12 mm. Survival curves were graphed and 
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Figure 21. Time-course pre-immunization studies with 2 shots SA-4-1BBL against TC-1. 
C57BL/6 mice were immunized twice with SA-4-1BBL (25 µg s.c., 2 weeks apart), 
followed by TC-1 challenge (1 x 10
5 
cells s.c.) 1 day (A) or 1 week (B), after the 2
nd
 
immunization. Tumor measurements were recorded twice a week using calipers and mice 
were euthanized when tumor average diameter ≥ 12 mm. Survival curves were graphed 
and log-rank tests were applied between groups using GraphPad software, with p ≤ 0.05 
to be significant.  








2 shots SA-4-1BBL, 1 day later TC-1





























2 shots SA-4-1BBL, 1 day later TC-1






















2 shots SA-4-1BBL, 1 week later TC-1





















2 shots SA-4-1BBL, 1 week later TC-1




















Figure 22. Time-course pre-immunization studies continuation with 2 shots SA-4-1BBL 
against TC-1. C57BL/6 mice were immunized twice with SA-4-1BBL (25 µg s.c., 2 
weeks apart), followed by TC-1 challenge (1 x 10
5
 s.c.) 4 weeks and 8 weeks (A) or 12 
weeks (B), after the 2
nd
 immunization. Tumor measurements were recorded twice a week 
using calipers and mice were euthanized when tumor average diameter ≥ 12 mm. 
Survival curves were graphed and log-rank tests were applied between groups using 
























T C -1  c o n tro l














Figure 23. SA-4-1BBL establishes significant long-term immune memory against TC-1. 
 
To study TC-1 recurrences, a group of naïve C57BL/6 mice were immunized twice with 
SA-4-1BBL (2 weeks apart), followed by 1
st
 TC-1 challenge 2 weeks after the second 
immunization. A second group of mice was treated exactly the same with additional 
vaccination (50 µg E7-P1 peptide + 25 µg SA-4-1BBL) 8 days after 1
st
 TC-1 challenge.   
Mice in both groups were monitored for a period of 60 days after 1
st
 tumor injection. At 
the end of day 60, tumor free mice were rechallenged with a 2
nd
 shot of TC-1 and 
monitored for additional 80 days. Tumors were measured twice a week using calipers and 
mice were euthanized when average tumor diameter ≥ 12 mm. Survival curves were 
graphed and Log-rank test was applied to compare groups using GraphPad software, with 






























































Figure 24. SA-4-1BBL primarily generates long-term CD4 effector memory.   
C57BL/6 mice were immunized twice with SA-4-1BBL (2 weeks apart), followed by 
TC-1 challenge 8 weeks after 2
nd
 immunization. Mice were monitored 60 days post-
tumor challenge, after which tumor free mice were euthanized, spleens and draining 
lymph nodes harvested and stained for flow-cytometric phenotyping. For T-effector 













































































































Figure 25. SA-4-1BBL rejects tumors in a non-specific fashion. C57BL/6 mice were 
immunized twice with SA-4-1BBL (25 µg s.c., 2 weeks apart), followed by LLC (1 x 10
5
 
s.c.), or TC-1 (1 x 10
5 
s.c.) challenge 2 weeks after the 2
nd
 immunization. Tumor 
measurements were recorded twice a week using calipers and mice were euthanized when 
tumor average diameter ≥ 12 mm. Survival curves were graphed and log-rank stats were 
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Figure 26. Anti-SA humoral immune response did not contribute to the SA-4-1-BBL-
mediated rejection of tumors. Sera collected on Day 27 from SA-4-1BBL immunized 
mice (25µg on days 0 and 14 s.c.) were adoptively transferred to naïve C57BL/6 mice 
(200 µl i.v.) 24 hours prior TC-1 tumor challenge (1 x 10
5
 s.c.). Tumor diameters were 
measured with calipers twice a week. Animals were terminated when average tumor size 
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Figure 27. Depletion of NK cells negates SA-4-1BBL’s protective effect. Different 
groups of C57BL/6 mice were immunized twice with 25 µg SA-4-1BBL (2 weeks apart), 
followed by TC-1 (1 x 10
5 
s.c.) challenge 2 weeks after the 2
nd
 immunization. NK cells 
were depleted with anti-NK1.1 Ab clone PK136 (500 µg i.p.) 1 day before SA-4-1BBL 
immunizations or 1 day before TC-1 challenge. Tumor measurements were recorded 
twice a week using calipers and mice were euthanized when tumor average diameter ≥ 12 
mm or when experimental endpoints were reached. Survival curves were graphed and 
Log-rank test was applied to compare groups using GraphPad software, with p ≤ 0.05 to 
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Figure 28. Depletion of CD4 cells but not CD8 cells negates SA-4-1BBL’s protective 
effect. Different groups of C57BL/6 mice were immunized twice with 25 µg SA-4-1BBL 
(2 weeks apart), followed by TC-1 (1 x 10
5 
s.c.) challenge 2 weeks after the 2
nd
 
immunization. CD4 cells were depleted with anti-CD4 Ab clone GK1.5 (500 µg i.p.), 
while CD8 cells were depleted with anti-CD8 Ab clone 53.6.72 (500 µg i.p.) 1 day before 
SA-4-1BBL immunizations. Tumor measurements were recorded twice a week using 
calipers and mice were euthanized when tumor average diameter ≥ 12 mm or when 
experimental endpoints were reached. Survival curves were graphed and Log-rank test 
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Figure 29. CD4 cells are required during effector phase after TC-1 challenge. C57BL/6 
mice were immunized twice with 25 µg SA-4-1BBL (2 weeks apart), followed by TC-1 
(1 x 10
5 
s.c.) challenge 2 weeks after the 2
nd
 immunization. CD4 cells were depleted with 
anti-CD4 Ab clone GK1.5 (500 µg i.p.) 1 day before TC-1 injection. Tumor 
measurements were recorded twice a week using calipers and mice were euthanized when 



















Figure 30. B cells and antibodies are not involved in SA-4-1BBL-mediated tumor 
protection. C57BL/6 mice were immunized twice with 25 µg SA-4-1BBL (2 weeks 
apart), followed by TC-1 (1 x 10
5 
s.c.) challenge 2 weeks after the 2
nd
 immunization. B 
cells were depleted with anti-CD20 Ab clone 5D2 (200 µg i.p.) 1 day before SA-4-1BBL 
immunizations. Tumor measurements were recorded twice a week using calipers and 
mice were euthanized when tumor average diameter ≥ 12 mm or when experimental 
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Figure 31. SA-4-1BBL immunization is ineffective against TC-1 in 4C mice. Either 4C 
or wild type C57BL/6 mice were immunized twice with SA-4-1BBL (25 µg s.c.) 
followed by TC-1 challenge (1 x 10
5
 s.c.) 2 weeks later from 2
nd
 immunization. Tumor 
measurements were recorded twice a week using calipers and mice were euthanized when 
tumor average diameter ≥ 12 mm or when experimental endpoints were reached. Survival 
curves were graphed and Log-rank test was applied to compare groups using GraphPad 
software, with p ≤ 0.05 to be significant.   
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Figure 32. 4C splenocytes stimulated with SA have compromised proliferation.  
Four 4C and two C57BL/6 mice were immunized with 1 shot of SA-4-1BBL (25 µg s.c.). 
Seven days later, spleens were harvested, processed, and cultured in vitro for 48 hours in 
the presence or absence of SA stimulation (5 µg/ml). Cultures were pulsed with 
3
[H]-
thymidine for additional 16 hours and CPMs were recorded. Stimulation index (SI) = 
average cpm on assessment day with stimulation / average cpm on assessment day 



































Figure 33. SA-4-1BBL immunization is capable of generating anti-SA antibodies in 4C 
mice. 4C or wild type C57BL/6 mice were immunized twice with SA-4-1BBL (2 weeks 
apart), and sera were collected 1 week after 2
nd
 immunization (day 21), and at 
experimental endpoint when tumors expire. ELISA plates were coated overnight with 50 
ng of SA-4-1BBL protein. Next day plates were washed and incubated with serial 
dilutions of specified sera for 1.5 hours, after which goat-anti-mouse secondary antibody 
conjugated to HRP was added for 1 hour. Colorimetric reaction was generated using 
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Figure 34. Subtyping ELISA at tumor endpoints for 4C mice pre-immunized twice with 
SA-4-1BBL. ELISA plates were pre-coated with 100 ng of SA-4-1BBL overnight. 1/25 
dilution of positive sera is used the next day to test the IgG1, IgG2a, IgG2b, IgG3, IgM, 










































Figure 35. SA-4-1BBL vs. SA+3H3: SA-4-1BBL as a bona fide novel 
immunomodulatory molecule. Different groups of C57BL/6 mice were immunized twice 
with either SA alone (12.5 µg s.c.), 3H3 alone (100 µg s.c.), SA + 3H3, or SA-4-1BBL 
(25 µg s.c.), followed by TC-1 (1 x 10
5 
s.c.) challenge 2 weeks after the 2
nd
 
immunization. Tumor measurements were recorded twice a week using calipers and mice 
were euthanized when tumor average diameter ≥ 12 mm or when experimental endpoints 
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Figure 36. Immunization with 3H3 reduces NK cell percentages in spleen lymphocyte 
population. C57BL/6 mice were immunized twice (2 weeks apart) with either (12.5 µg 
SA + 100 µg 3H3 n=4) or (25 µg SA-4-1BBL n=4). Three days later, spleens were 

























































































Figure 37. Immunization with 3H3 reduces NK absolute cell numbers in spleen 
lymphocyte population. C57BL/6 mice were immunized twice (2 weeks apart) with either 
(12.5 µg SA + 100 µg 3H3 n=4) or (25 µg SA-4-1BBL n=4). Three days later, spleens 
were harvested, processed, and stained for flow cytometric phenoytping. CD4 T cells 
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Figure 38. Immunization with 3H3 reduces NK cell percentages in draining lymph 
nodes’ lymphocyte population. C57BL/6 mice were immunized twice (2 weeks apart) 
with either (12.5 µg SA + 100 µg 3H3 n=4) or (25 µg SA-4-1BBL n=4). Three days later, 
draining lymph nodes were harvested, processed, and stained for flow cytometric 





















































































Figure 39. Immunization with SA+3H3 vs. SA-4-1BBL absolute cell numbers profile in 
draining lymph nodes. C57BL/6 mice were immunized twice (2 weeks apart) with either 
(12.5 µg SA + 100 µg 3H3 n=4) or (25 µg SA-4-1BBL n=4). Three days later, draining 
lymph nodes were harvested, processed, and stained for flow cytometric phenoytping. 
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Figure 40. SA+ 3H3 immunization shuts down antibody production. C57BL/6 mice were 
immunized twice with 12.5 µg SA + 100 µg 3H3 Ab. Sera were collected 1 week after 
the 2
nd
 immunization and again at tumor endpoints and subjected to anti-SA ELISA.   
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